DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Jamie Shortall Grant Officer
Award ceiling
—Award floor
—Posted
May 4, 2026Closes
Sep 30, 2026Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Science and Technology and other Research and Development
Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Description
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.